Emergent Biosolutions (EBS) Competitors

$8.15 +0.21 (+2.61%)

Closing price 05/18/2026 03:59 PM Eastern

Extended Trading

$8.22 +0.07 (+0.83%)

As of 05/18/2026 07:59 PM Eastern

EBS vs. JNJ, INVA, NVAX, ZBIO, and MNKD

Should you buy Emergent Biosolutions stock or one of its competitors? MarketBeat compares Emergent Biosolutions with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Emergent Biosolutions include Johnson & Johnson (JNJ), Innoviva (INVA), Novavax (NVAX), Zenas BioPharma (ZBIO), and MannKind (MNKD). These companies are all part of the "medical" sector.

How does Emergent Biosolutions compare to Johnson & Johnson?

Emergent Biosolutions (NYSE:EBS) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90M	0.57	$52.60M	-$0.28	N/A
Johnson & Johnson	$94.19B	5.85	$26.80B	$8.65	26.45

Emergent Biosolutions has a beta of 2.33, indicating that its stock price is 133% more volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Emergent Biosolutions presently has a consensus target price of $12.00, indicating a potential upside of 47.29%. Johnson & Johnson has a consensus target price of $253.04, indicating a potential upside of 10.60%. Given Emergent Biosolutions' higher probable upside, analysts plainly believe Emergent Biosolutions is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74

Johnson & Johnson has a net margin of 21.83% compared to Emergent Biosolutions' net margin of -1.27%. Johnson & Johnson's return on equity of 32.60% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-1.27%	10.76%	4.22%
Johnson & Johnson	21.83%	32.60%	13.29%

In the previous week, Johnson & Johnson had 88 more articles in the media than Emergent Biosolutions. MarketBeat recorded 89 mentions for Johnson & Johnson and 1 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.22 beat Emergent Biosolutions' score of 0.50 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Johnson & Johnson	65 Very Positive mention(s)	8 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	2 Very Negative mention(s)	Positive

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 6.0% of Emergent Biosolutions shares are owned by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Johnson & Johnson beats Emergent Biosolutions on 12 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to Innoviva?

Emergent Biosolutions (NYSE:EBS) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Emergent Biosolutions has a beta of 2.33, suggesting that its share price is 133% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Innoviva has lower revenue, but higher earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90M	0.57	$52.60M	-$0.28	N/A
Innoviva	$411.33M	3.91	$271.17M	$6.01	3.63

78.4% of Emergent Biosolutions shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 6.0% of Emergent Biosolutions shares are held by insiders. Comparatively, 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Innoviva had 1 more articles in the media than Emergent Biosolutions. MarketBeat recorded 2 mentions for Innoviva and 1 mentions for Emergent Biosolutions. Innoviva's average media sentiment score of 0.64 beat Emergent Biosolutions' score of 0.50 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has a net margin of 119.89% compared to Emergent Biosolutions' net margin of -1.27%. Innoviva's return on equity of 33.33% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-1.27%	10.76%	4.22%
Innoviva	119.89%	33.33%	22.67%

Emergent Biosolutions presently has a consensus target price of $12.00, indicating a potential upside of 47.29%. Innoviva has a consensus target price of $36.20, indicating a potential upside of 66.06%. Given Innoviva's stronger consensus rating and higher probable upside, analysts plainly believe Innoviva is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Innoviva beats Emergent Biosolutions on 13 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to Novavax?

Emergent Biosolutions (NYSE:EBS) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Novavax has lower revenue, but higher earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90M	0.57	$52.60M	-$0.28	N/A
Novavax	$596.34M	2.46	$440.30M	-$0.58	N/A

Emergent Biosolutions has a net margin of -1.27% compared to Novavax's net margin of -14.73%. Emergent Biosolutions' return on equity of 10.76% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-1.27%	10.76%	4.22%
Novavax	-14.73%	-14.82%	1.23%

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 6.0% of Emergent Biosolutions shares are owned by insiders. Comparatively, 1.0% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Emergent Biosolutions presently has a consensus price target of $12.00, indicating a potential upside of 47.29%. Novavax has a consensus price target of $12.13, indicating a potential upside of 35.78%. Given Emergent Biosolutions' higher possible upside, research analysts plainly believe Emergent Biosolutions is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

Emergent Biosolutions has a beta of 2.33, suggesting that its share price is 133% more volatile than the broader market. Comparatively, Novavax has a beta of 2.37, suggesting that its share price is 137% more volatile than the broader market.

In the previous week, Novavax had 7 more articles in the media than Emergent Biosolutions. MarketBeat recorded 8 mentions for Novavax and 1 mentions for Emergent Biosolutions. Novavax's average media sentiment score of 0.74 beat Emergent Biosolutions' score of 0.50 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Emergent Biosolutions and Novavax tied by winning 8 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Emergent Biosolutions (NYSE:EBS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Emergent Biosolutions has higher revenue and earnings than Zenas BioPharma. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	106.75	-$377.74M	-$8.47	N/A
Emergent Biosolutions	$742.90M	0.57	$52.60M	-$0.28	N/A

78.4% of Emergent Biosolutions shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Zenas BioPharma currently has a consensus price target of $44.29, suggesting a potential upside of 161.89%. Emergent Biosolutions has a consensus price target of $12.00, suggesting a potential upside of 47.29%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Zenas BioPharma is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Zenas BioPharma had 13 more articles in the media than Emergent Biosolutions. MarketBeat recorded 14 mentions for Zenas BioPharma and 1 mentions for Emergent Biosolutions. Zenas BioPharma's average media sentiment score of 0.86 beat Emergent Biosolutions' score of 0.50 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Emergent Biosolutions	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zenas BioPharma has a beta of -0.61, indicating that its stock price is 161% less volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.33, indicating that its stock price is 133% more volatile than the broader market.

Zenas BioPharma has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -1.27%. Emergent Biosolutions' return on equity of 10.76% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Emergent Biosolutions	-1.27%	10.76%	4.22%

Summary

Zenas BioPharma beats Emergent Biosolutions on 9 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to MannKind?

MannKind (NASDAQ:MNKD) and Emergent Biosolutions (NYSE:EBS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, MannKind had 11 more articles in the media than Emergent Biosolutions. MarketBeat recorded 12 mentions for MannKind and 1 mentions for Emergent Biosolutions. MannKind's average media sentiment score of 0.88 beat Emergent Biosolutions' score of 0.50 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Emergent Biosolutions	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

49.6% of MannKind shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 2.6% of MannKind shares are owned by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Emergent Biosolutions has a net margin of -1.27% compared to MannKind's net margin of -6.63%. Emergent Biosolutions' return on equity of 10.76% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Emergent Biosolutions	-1.27%	10.76%	4.22%

MannKind presently has a consensus target price of $8.84, suggesting a potential upside of 195.78%. Emergent Biosolutions has a consensus target price of $12.00, suggesting a potential upside of 47.29%. Given MannKind's stronger consensus rating and higher possible upside, research analysts plainly believe MannKind is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MannKind has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.33, indicating that its stock price is 133% more volatile than the broader market.

Emergent Biosolutions has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	2.65	$5.86M	-$0.07	N/A
Emergent Biosolutions	$742.90M	0.57	$52.60M	-$0.28	N/A

Summary

Emergent Biosolutions beats MannKind on 9 of the 16 factors compared between the two stocks.

Get Emergent Biosolutions News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EBS vs. The Competition

Export

Metric	Emergent Biosolutions	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$410.06M	$3.31B	$6.25B	$22.75B
Dividend Yield	N/A	2.34%	2.80%	4.13%
P/E Ratio	-29.10	18.13	20.86	29.86
Price / Sales	0.57	274.73	549.93	24.03
Price / Cash	2.17	55.27	27.48	18.80
Price / Book	0.82	6.57	9.67	4.59
Net Income	$52.60M	$24.35M	$3.56B	$1.07B
7 Day Performance	-4.21%	-2.53%	-1.70%	-0.98%
1 Month Performance	-7.49%	-3.55%	-2.66%	-1.30%
1 Year Performance	20.52%	53.51%	30.03%	22.13%

Emergent Biosolutions Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EBS Emergent Biosolutions	1.8554 of 5 stars	$8.15 +2.6%	$12.00 +47.3%	+22.4%	$410.06M	$742.90M	N/A	2,420	Gap Up
JNJ Johnson & Johnson	4.6238 of 5 stars	$221.36 +0.0%	$252.48 +14.1%	+51.2%	$532.77B	$94.19B	25.59	138,200	Trending News
INVA Innoviva	3.8162 of 5 stars	$22.52 -1.6%	$36.20 +60.7%	+17.3%	$1.70B	$411.33M	3.75	100	Analyst Downgrade
NVAX Novavax	2.1115 of 5 stars	$9.50 -6.0%	$12.13 +27.6%	+32.7%	$1.66B	$1.12B	N/A	1,990	High Trading Volume
ZBIO Zenas BioPharma	3.5363 of 5 stars	$20.40 +3.9%	$44.14 +116.4%	+61.5%	$1.13B	$10M	N/A	N/A	News Coverage Earnings Report Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EBS) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Emergent Biosolutions (EBS) Competitors

EBS vs. JNJ, INVA, NVAX, ZBIO, and MNKD

How does Emergent Biosolutions compare to Johnson & Johnson?

Summary

How does Emergent Biosolutions compare to Innoviva?

Summary

How does Emergent Biosolutions compare to Novavax?

Summary

How does Emergent Biosolutions compare to Zenas BioPharma?

Summary

How does Emergent Biosolutions compare to MannKind?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS vs. The Competition

Emergent Biosolutions Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Emergent Biosolutions (EBS) Competitors

EBS vs. JNJ, INVA, NVAX, ZBIO, and MNKD

How does Emergent Biosolutions compare to Johnson & Johnson?

Which has better valuation & earnings, EBS or JNJ?

Which has more risk & volatility, EBS or JNJ?

Do analysts recommend EBS or JNJ?

Is EBS or JNJ more profitable?

Does the media favor EBS or JNJ?

Do institutionals and insiders believe in EBS or JNJ?

Summary

How does Emergent Biosolutions compare to Innoviva?

Which has more volatility and risk, EBS or INVA?

Which has preferable valuation and earnings, EBS or INVA?

Do insiders & institutionals believe in EBS or INVA?

Does the media favor EBS or INVA?

Is EBS or INVA more profitable?

Do analysts recommend EBS or INVA?

Summary

How does Emergent Biosolutions compare to Novavax?

Which has higher valuation and earnings, EBS or NVAX?

Is EBS or NVAX more profitable?

Do insiders & institutionals have more ownership in EBS or NVAX?

Do analysts rate EBS or NVAX?

Which has more volatility and risk, EBS or NVAX?

Does the media prefer EBS or NVAX?

Summary

How does Emergent Biosolutions compare to Zenas BioPharma?

Which has better earnings & valuation, ZBIO or EBS?

Do insiders and institutionals have more ownership in ZBIO or EBS?

Do analysts prefer ZBIO or EBS?

Does the media favor ZBIO or EBS?

Which has more risk & volatility, ZBIO or EBS?

Is ZBIO or EBS more profitable?

Summary

How does Emergent Biosolutions compare to MannKind?

Does the media refer more to MNKD or EBS?

Do insiders & institutionals hold more shares of MNKD or EBS?

Is MNKD or EBS more profitable?

Do analysts recommend MNKD or EBS?

Which has more volatility and risk, MNKD or EBS?

Which has preferable valuation and earnings, MNKD or EBS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS vs. The Competition

Emergent Biosolutions Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools